CN119679935A - Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标 - Google Patents

Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标 Download PDF

Info

Publication number
CN119679935A
CN119679935A CN202411436609.3A CN202411436609A CN119679935A CN 119679935 A CN119679935 A CN 119679935A CN 202411436609 A CN202411436609 A CN 202411436609A CN 119679935 A CN119679935 A CN 119679935A
Authority
CN
China
Prior art keywords
bcma
cell
cells
gamma
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411436609.3A
Other languages
English (en)
Chinese (zh)
Inventor
H·亚当斯三世
R·维罗纳
A·P·凯特
E·F·埃尔德林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amsterdam University Medical Center Foundation
Janssen Biotech Inc
Original Assignee
Amsterdam University Medical Center Foundation
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amsterdam University Medical Center Foundation, Janssen Biotech Inc filed Critical Amsterdam University Medical Center Foundation
Priority claimed from CN202280038598.6A external-priority patent/CN118043070A/zh
Publication of CN119679935A publication Critical patent/CN119679935A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202411436609.3A 2021-05-28 2022-05-26 Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标 Pending CN119679935A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163194470P 2021-05-28 2021-05-28
US63/194470 2021-05-28
US202163209694P 2021-06-11 2021-06-11
US63/209694 2021-06-11
CN202280038598.6A CN118043070A (zh) 2021-05-28 2022-05-26 Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标
PCT/EP2022/064362 WO2022248642A1 (en) 2021-05-28 2022-05-26 Bcma as a target for t cell redirecting antibodies in b cell lymphomas

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202280038598.6A Division CN118043070A (zh) 2021-05-28 2022-05-26 Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标

Publications (1)

Publication Number Publication Date
CN119679935A true CN119679935A (zh) 2025-03-25

Family

ID=82115891

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202411436609.3A Pending CN119679935A (zh) 2021-05-28 2022-05-26 Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标

Country Status (10)

Country Link
US (1) US20220411525A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347039A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024519545A (cg-RX-API-DMAC7.html)
KR (1) KR20240014482A (cg-RX-API-DMAC7.html)
CN (1) CN119679935A (cg-RX-API-DMAC7.html)
AU (1) AU2022281104A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024822A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221399A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014139A (cg-RX-API-DMAC7.html)
WO (1) WO2022248642A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment

Also Published As

Publication number Publication date
BR112023024822A2 (pt) 2024-02-20
WO2022248642A1 (en) 2022-12-01
US20220411525A1 (en) 2022-12-29
CA3221399A1 (en) 2022-12-01
EP4347039A1 (en) 2024-04-10
KR20240014482A (ko) 2024-02-01
MX2023014139A (es) 2023-12-13
JP2024519545A (ja) 2024-05-15
AU2022281104A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
KR102928003B1 (ko) Siglec-15를 위한 항체 및 이의 사용 방법
US10604580B2 (en) Combination therapies with anti-CD38 antibodies
AU2017257505B2 (en) Compositions comprising coformulation of anti-PD-L1 and Anti-CTLA-4 antibodies
CN116249548A (zh) 用于治疗多发性骨髓瘤的方法
US20240209061A1 (en) Fusion proteins and uses thereof
US12110337B2 (en) Anti-CD27 antibodies and uses thereof
JP2016534090A (ja) Cd38アゴニストの医学的使用
WO2020185739A1 (en) Anti-icos antibodies for the treatment of cancer
CA3232806A1 (en) B7-h4 antibody-drug conjugates for the treatment of cancer
WO2022058445A1 (en) Methods for treating multiple myeloma
US20220411525A1 (en) Bcma as a target for t cell redirecting antibodies in b cell lymphomas
CA3253669A1 (en) Anti-CD39 antibodies and their use
JP2024097985A (ja) 抗gitr抗体およびその使用
KR20240099362A (ko) 혈액암에 대한 lag-3 길항제 요법
EP4011918A1 (en) Dual-specific protein
CN118043070A (zh) Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标
TW202328206A (zh) 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
CN117957253A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
HK40110611A (en) Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EA047743B1 (ru) Антитела к gitr и варианты их применения
CA3124168A1 (en) Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination